Braveheart Bio, Inc.
Support and Resistance Levels
Past performance
News About BRVE
All events for BRVE
All deals for BRVE
Financial Ratios
Financial Statements
BRVE vs Sector & Peers
About Braveheart Bio, Inc.
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA. Website braveheart.bio
Headquarters San Francisco, CA, US